X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MERCK LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA MERCK LTD TORRENT PHARMA/
MERCK LTD
 
P/E (TTM) x 29.3 34.8 84.2% View Chart
P/BV x 5.6 3.9 143.0% View Chart
Dividend Yield % 1.0 0.7 134.6%  

Financials

 TORRENT PHARMA   MERCK LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
MERCK LTD
Dec-16
TORRENT PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,7681,060 166.8%   
Low Rs1,186623 190.3%   
Sales per share (Unadj.) Rs346.1632.4 54.7%  
Earnings per share (Unadj.) Rs55.245.7 120.7%  
Cash flow per share (Unadj.) Rs73.362.3 117.6%  
Dividends per share (Unadj.) Rs14.0011.00 127.3%  
Dividend yield (eoy) %0.91.3 72.5%  
Book value per share (Unadj.) Rs257.1388.8 66.1%  
Shares outstanding (eoy) m169.2216.60 1,019.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.31.3 320.7%   
Avg P/E ratio x26.818.4 145.4%  
P/CF ratio (eoy) x20.113.5 149.2%  
Price / Book Value ratio x5.72.2 265.4%  
Dividend payout %25.424.1 105.5%   
Avg Mkt Cap Rs m249,88713,969 1,788.9%   
No. of employees `00011.81.6 744.2%   
Total wages/salary Rs m9,9341,487 668.2%   
Avg. sales/employee Rs Th4,971.56,631.9 75.0%   
Avg. wages/employee Rs Th843.2939.2 89.8%   
Avg. net profit/employee Rs Th792.4479.4 165.3%   
INCOME DATA
Net Sales Rs m58,56910,498 557.9%  
Other income Rs m2,233242 921.2%   
Total revenues Rs m60,80210,741 566.1%   
Gross profit Rs m13,7731,135 1,213.1%  
Depreciation Rs m3,069276 1,114.0%   
Interest Rs m2,0560-   
Profit before tax Rs m10,8811,102 987.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545343 450.1%   
Profit after tax Rs m9,336759 1,230.2%  
Gross profit margin %23.510.8 217.4%  
Effective tax rate %14.231.1 45.6%   
Net profit margin %15.97.2 220.5%  
BALANCE SHEET DATA
Current assets Rs m53,8416,410 840.0%   
Current liabilities Rs m31,6128,828 358.1%   
Net working cap to sales %38.0-23.0 -164.7%  
Current ratio x1.70.7 234.6%  
Inventory Days Days9758 168.5%  
Debtors Days Days8438 218.2%  
Net fixed assets Rs m42,0791,406 2,992.0%   
Share capital Rs m846166 509.8%   
"Free" reserves Rs m42,6556,286 678.6%   
Net worth Rs m43,5016,455 674.0%   
Long term debt Rs m22,4080-   
Total assets Rs m101,2508,828 1,146.9%  
Interest coverage x6.3NM-  
Debt to equity ratio x0.50-  
Sales to assets ratio x0.61.2 48.6%   
Return on assets %11.38.6 130.9%  
Return on equity %21.511.8 182.5%  
Return on capital %19.617.1 114.9%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m20,066959 2,092.9%   
Fx outflow Rs m5,3042,612 203.1%   
Net fx Rs m14,762-1,653 -893.0%   
CASH FLOW
From Operations Rs m10,1271,070 946.1%  
From Investments Rs m-7,869-750 1,049.6%  
From Financial Activity Rs m-1,918-150 1,280.4%  
Net Cashflow Rs m212171 123.8%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 7.0 18.2 38.6%  
FIIs % 12.6 1.0 1,260.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 29.1 30.2%  
Shareholders   26,511 28,591 92.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex & Nifty Open at Record Highs; Banking & PSU Stocks Rally(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.46% while the Hang Seng is up 0.28%. The Shanghai Composite is trading up by 0.43%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 18, 2018 11:29 AM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - AJANTA PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS